Bone histomorphometry of transiliac paired bone biopsies after 6 or 12 months of treatment with oral strontium ranelate in 387 osteoporotic women: Randomized comparison to alendronate

Journal of Bone and Mineral Research

Volumn 29, Issue 3, 2014, Pages 618-628

  Chavassieux, Pascale ^a   Meunier, Pierre J ^a   Roux, Jean Paul ^a   Portero Muzy, Nathalie ^a   Pierre, Marlène ^a   Chapurlat, Roland ^a  

^a UNIVERSITÉ DE LYON   (France)

Author keywords

alendronate; histomorphometry; osteoporosis; paired biopsy; strontium ranelate

Indexed keywords

ALENDRONATE; HISTOMORPHOMETRY; OSTEOPOROSIS; PAIRED BIOPSY; STRONTIUM RANELATE;

ADMINISTRATION, ORAL; ALENDRONATE; BIOPSY; BONE AND BONES; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS; THIOPHENES;

EID: 84894464281     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2074     Document Type: Article

References (41)

1. Seeman E, Delmas PD., Bone quality-the material and structural basis of bone strength and fragility. N Engl J Med. 2006; 354: 2250-61.
2. Chavassieux P, Seeman E, Delmas PD., Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease. Endocr Rev. 2007; 28 (2): 151-64.
3. Canalis E, Hott M, Deloffre P, Tsouderos Y, Marie PJ., The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone. 1996; 18 (6): 517-23.
4. Baron R, Tsouderos Y., In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation. Eur J Pharmacol. 2002; 450 (1): 11-7.
5. Takahashi N, Sasaki T, Tsouderos Y, Suda T., S1911-2 inhibits osteoclastic bone resorption in vitro. J Bone Miner Res. 2003; 18 (6): 1082-7.
6. Marie PJ, Hott M, Modrowski D, et al. An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res. 1993; 8: 607-15.
7. Bain SD, Jerome C, Shen V, Dupin-Roger I, Ammann P., Strontium ranelate improves bone strength in ovariectomized rat by positively influencing bone resistance determinants. Osteoporos Int. 2009; 20 (8): 1417-28.
8. Saidak Z, Hay E, Marty C, Barbara A, Marie PJ., Strontium ranelate rebalances bone marrow adipogenesis and osteoblastogenesis in senescent osteopenic mice through NFATc/Maf and Wnt signaling. Ageing Cell. 2012; 11: 467-74.
9. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004; 350 (5): 459-68.
10. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab. 2005; 90 (5): 2816-22.
11. Reginster JY, Felsenberg D, Boonen S, et al. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum. 2008; 58 (6): 1687-95.
12. Roux C, Fechtenbaum J, Kolta S, Isaia G, Andia JB, Devogelaer JP., Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis. Ann Rheum Dis. 2008; 67 (12): 1736-8.
13. Seeman E, Boonen S, Borgström F, et al. Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age. Bone. 2010; 46 (4): 1038-42.
14. Recker RR, Marin F, Ish-Shalom S, et al. Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J Bone Miner Res. 2009; 24 (8): 1358-68.
15. Arlot ME, Jiang Y, Genant HK, et al. Histomorphometric and μCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J Bone Miner Res. 2008; 23 (2): 215-22.
16. Chavassieux P, Arlot M, Meunier PJ., Clinical use of bone biopsy. In:, Marcus R, Feldman D, Kelsey J, editors. Osteoporosis vol. 2, 2nd ed. San Diego: Academic Press; p. 501-9. 2001.
17. Dempster DW, Compston JE, Drezner MK, et al. Standardized nomenclature, symbols and units for bone histomorphometry. A 2012 update of the report of the ASBMR histomorphometry nomenclature committee. J Bone Miner Res. 2013; 28: 1-16.
18. Parfitt AM, Mathews CH, Villanueva AR, Kleerekoper M, Frame B, Rao DS., Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanisms of bone loss. J Clin Invest. 1983; 72 (4): 1396-409.
19. Recker RR, Kimmel DB, Dempster D, et al. Issues in modern bone histomorphometry. Bone. 2011; 49: 955-64.
20. Chavassieux P, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ., Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest. 1997; 100: 1475-80.
21. Bonnelye E, Chabadel A, Saltel F, Jurdic P., Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone. 2008; 42 (1): 129-38.
22. Caverzasio J., Strontium ranelate promotes osteoblastic cell replication through at least two different mechanisms. Bone. 2008; 42 (6): 1131-6.
23. Meunier PJ, Slosman DO, Delmas PD, et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis-a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab. 2002; 87 (5): 2060-6.
24. Reginster JY, Deroisy R, Dougados M, Jupsin I, Colette J, Roux C., Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial. Osteoporos Int. 2002; 13 (12): 925-31.
25. Brixen K, Krogsggaard K, Christgau S, Weis M, Eastell R., Effects of three doses of strontium malonate (NB S101) on markers of bone turnover: the STRONG study. Calcif Tissue Int. 2008; 82 (Suppl 1): S217.
26. Collette J, Bruyère O, Kaufman JM, et al. Vertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone turnover. Osteoporos Int. 2010; 21: 233-41.
27. Pors Nielsen S, Slosman D, Sorensen OH, et al. Influence of strontium on bone mineral density and bone mineral content measurements by dual X-ray absorptiometry. J Clin Densitom. 1999; 2: 371-9.
28. Farlay D, Boivin G, Panczer G, Lalande A, Meunier PJ., Long-term strontium ranelate administration in monkeys preserves characteristics of bone mineral crystals and degree of mineralization of bone. J Bone Miner Res. 2005; 20 (9): 1569-78.
29. Roschger P, Manjubala I, Zoeger N, et al. Bone material quality in transiliac bone biopsies of postmenopausal osteoporotic women after 3 years of strontium ranelate treatment. J Bone Miner Res. 2010; 25 (4): 891-900.
30. Ammann P, Badoud I, Barraud S, Dayer R, Rizzoli R., Strontium ranelate treatment improves trabecular and cortical intrinsic bone tissue quality, a determinant of bone strength. J Bone Miner Res. 2007; 22 (9): 1419-25.
31. Boyd SK, Szabo E, Ammann P., Increased bone strength is associated with improved bone microarchitecture in intact female rats treated with strontium ranelate: a finite element analysis study. Bone. 2011; 48 (5): 1109-16.
32. Smith BL, Schäffer TE, Viani M, et al. Molecular mechanistic origin of the toughness of natural adhesives, fibres and composites. Nature. 1999; 399: 761-3.
33. Thompson JB, Kindt JH, Drake B, Hansma HG, Morse DE, Hansma PK., Bone indentation recovery time correlates with bond reforming time. Nature. 2001; 414: 773-6.
34. Fantner GE, Hassenkam T, Kindt JH, et al. Sacrificial bonds and hidden length dissipate energy as mineralized fibrils separate during bone fracture. Nat Mater. 2005; 4: 612-6.
35. Hartmann MA, Fratzl P., Sacrificial ionic bonds need to be randomly distributed to provide shear deformability. Nano Lett. 2009; 9: 3603-7.
36. Rizzoli R, Chapurlat RD, Laroche JM, et al. Effects of strontium ranelate and alendronate on bone microstructure in women with osteoporosis. Results of a 2-year study. Osteoporos Int. 2012; 23: 305-15.
37. Ammann P, Rizzoli R., Strontium ranelate treatment improves bone material quality in human bone biopsy specimens compared with alendronate. Osteoporos Int. 2012; 23 (Suppl 2): S246.
38. Portero-Muzy NR, Chavassieux PM, Bouxsein ML, Gineyts E, Garnero P, Chapurlat RD., Early effects of zoledronic acid and teriparatide on bone microarchitecture, remodeling and collagen crosslinks: comparison between iliac crest and lumbar vertebra in ewes. Bone. 2012; 51 (4): 714-9.
39. Hildebrand T, Laib A, Müller R, Dequeker J, Rüegsegger P., Direct three-dimensional morphometric analysis of human cancellous bone: microstructural data from spine, femur, iliac crest, and calcaneus. Bone Miner Res. 1999; 14 (7): 1167-74.
40. Cohen A, Dempster DW, Müller R, et al. Assessment of trabecular and cortical architecture and mechanical competence of bone by high-resolution peripheral computed tomography: comparison with transiliac bone biopsy. Osteoporos Int. 2010; 21 (2): 263-73.
41. Bakker AD, Zandieh-Doulabi B, Klein-Nulend J., Strontium ranelate affects signaling from mechanically-stimulated osteocytes towards osteoclasts and osteoblasts. Bone. 2013; 53: 112-9.